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Abstract
Lithocholic acid (LA) conjugates interact with M3 receptors, the muscarinic receptor subtype that modulates colon cancer cell
proliferation. This observation prompted us to examine the action of bile acids on two human colon cancer cell lines: H508, which expresses
M3 receptors, and SNU-C4, which does not. Cellular proliferation was determined using a colorimetric assay. Interaction with muscarinic
receptors was determined by measuring inhibition of muscarinic radioligand binding and changes in cellular inositol phosphate (IP)
formation. Lithocholyltaurine (LCT) caused a dose-dependent increase in H508 cell proliferation that was not observed in SNU-C4 cells.
After a 6-day incubation with 300 AM LCT, H508 cell proliferation increased by 200% compared to control. Moreover, in H508 cells, LCT
caused a dose-dependent inhibition of radioligand binding and an increase in IP formation. LCT did not alter the rate of apoptosis in H508 or
SNU-C4 cells. These data indicate that, at concentrations achievable in the gut, LA derivatives interact with M3 muscarinic receptors on
H508 human colon cancer cells, thereby causing an increase in IP formation and cell proliferation. This suggests a mechanism whereby
alterations in intestinal bile acids may affect the growth of colon cancer cells.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
In the United States, colorectal cancer is the second most
common cause of cancer death [1]. Experimental data
support the concept that most of these cancers arise as a
consequence of progression from normal colonic mucosa to
adenomatous polyp to cancer, associated with the accumu-
lation of somatic genetic alterations [2]. These alterations
include mutations of both oncogenes and suppressor genes
[2]. Environmental factors, such as dietary components and
fecal bile acid concentrations, may play an important
promoting role in this process [3–6].
Epidemiological studies in humans have associated the
development of colorectal cancer with elevations in fecal bile
acid concentration, particularly lithocholic acid (LA) [3–5]
(although the term bile acid refers to the protonated form and
bile salt the ionized form of these molecules, in this paper, as
is common in the literature, these terms will be used inter-
changeably, and bile salt nomenclature will conform to
recommendations by Hofmann et al. [7]). It has been reported
that the ratio of lithocholate to deoxycholate (LA/DCA ratio)
is 2-fold greater in persons with colon cancer compared to
controls [8]. There has been a suggestion that by altering the
delivery of conjugated bile acids to the colon, particularly
secondary bile acids to the cecum and ascending colon
(increased LA/DCA ratio), cholecystectomy increases the
incidence of colon cancer [9–11]. Animal data, particularly
from rats treated with carcinogens, indicate that direct instil-
lation, or other means of increasing fecal bile acids, augments
the development of colon cancer [12–14], and that the timing
of interventions is important to the outcome [15]. In some
studies, mucosal toxicity was noted following intrarectal
0925-4439/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0925 -4439 (02 )00115 -1
Abbreviations: ACh, acetylcholine; carbachol, carbamylcholine; FBS,
fetal bovine serum; IP, inositol phosphate; LA, lithocholic acid; DCA,
deoxycholic acid; LCG, lithocholylglycine; LCT, lithocholyltaurine; MAP
kinase, mitogen-activated protein kinase; NMS, N-[methyl]scopolamine; S-
LCT, 3-O-sulfate LCT; SRB, sulforhodamine B
* Corresponding author. Tel.: +1-501-686-6217; fax: +1-501-686-6248.
E-mail address: raufmanjeanpierre@uams.edu (J.-P. Raufman).
www.bba-direct.com
Biochimica et Biophysica Acta 1588 (2002) 48–55
instillation of bile acids. In rats fed LA, the risk of aberrant
colonic epithelial growth is increased compared to those fed
deoxycholic acid (DCA) [16]. The major beneficial effects of
dietary elements like fiber and calcium are thought to result
from binding of bile acids in the gut lumen, thereby inhibiting
their damaging effects on epithelial cells and potentiating
actions on experimental colon cancer [17–19]. Absent from
this body of largely circumstantial evidence is a defined
mechanism whereby bile acids promote the development or
progression of colon cancer.
Recently, experimental findings in our laboratories sug-
gested a possible mechanism that explains how bile acids
might stimulate colon cancer cell proliferation. In the course
of examining the actions of bile acids on pepsinogen secre-
tion from gastric chief cells, Raufman et al. [20] reported that
taurine conjugates of LA, but not other bile acids, bind to
muscarinic receptors, increase cellular inositol phosphates
(IP), and stimulate secretion by a cholinergic mechanism.
Molecular cloning studies revealed the existence of five
muscarinic receptor genes, designated M1–5 based on their
order of cloning [21,22]. Because gastric chief cells express
M3 muscarinic cholinergic receptors [23,24], we concluded
that these actions were mediated by interaction of lithocho-
lyltaurine (LCT) with that receptor subtype. These findings
have been confirmed in preliminary studies using Chinese
hamster ovary cells transfected with the gene for the M3
muscarinic receptor [25]. Frucht et al. [26,27] reported that
several colon cancer cell lines express M3 receptors, and that
activation of these receptors with cholinergic agonists stim-
ulates an increase in IPs and cell proliferation. Together, these
observations suggest the possibility that the proliferative
effects of fecal bile acids, particularly LA conjugates, on
colonic neoplasia are mediated by cholinergic actions.
In the present study, we tested the hypothesis that
conjugated derivatives of LA interact with M3 muscarinic
receptors on colon cancer cells, thereby stimulating prolif-
eration. The specific aims of this study were to test the
ability of LA conjugates to bind to M3 receptors on H508
colon cancer cells, to activate post-receptor signaling mech-
anisms, and to stimulate cell proliferation. These actions
were compared to those of known cholinergic agents and to
the actions of the LCT metabolite, 3-O-sulfate LCT (S-
LCT). The SNU-C4 colon cancer cell line, which does not
express muscarinic receptors [27], was used as a control.
Our results support the hypothesis that chronic exposure of
colon cancer cells to fecal bile acids may promote growth of
neoplastic cells by a cholinergic mechanism.
2. Materials and methods
2.1. Cell lines and bile acids
Colon cancer cell lines (H508 and SNU-C4) were avail-
able in the investigator’s laboratories. Cancer cells were
grown in RPMI 1640 (ATCC) supplemented with 10% fetal
bovine serum (FBS) (Biowhittaker). Adherent cultures were
passaged weekly at subconfluence after trypsinization. Cul-
tures were maintained in incubators at 37 jC in an atmos-
phere of 5% CO2 and 95% air. LCT was from Sigma.
Lithocholylglycine (LCG) was from Steraloids. Stock sol-
utions of LCT and LCG (100 mM) were prepared using
DMSO (100%). The highest DMSO concentration in sol-
utions incubated with cells was 0.6%. Carbachol was from
CalBiochem. All other chemicals were obtained from Sigma
or Fisher.
2.2. Cytotoxicity assays
Potential cytotoxic actions of bile acids and other test
agents on H508 and SNU-C4 cells were examined by trypan
blue exclusion.
2.3. Cell proliferation assay
Cell proliferation was determined using the sulforhod-
amine B (SRB) colorimetric assay [28]. Cells were seeded
in 96-well plates (Corning Glass Works, Corning, NY) at
approximately 10% confluence and allowed to attach for 24
h. The growth medium was removed and fresh medium
without FBS and containing the indicated concentration of
test agent was added. Cells were incubated for the described
period of time at 37 jC in an atmosphere of 5% CO2 and
95% air. After incubation, cells were treated for 30 min with
0.4% (w/v) SRB dissolved in 1% acetic acid. Protein-bound
dye was extracted with 10 mM unbuffered Tris base.
Absorbance was measured at 560 nm using a computer-
interfaced, 96-well microtiter plate reader.
2.4. Caspase-3 assay
Caspase-3 activation is a key step in the regulation of
apoptosis [29,30]. H508 and SNU-C4 cellular caspase-3
activity was measured using a kit from Sigma. Cells (2–
4 105 cells/ml) were seeded in T75 flasks. Growth
medium was removed after 24 h and cells were incubated
with the indicated agent, containing no added FBS, for 3 or
6 days at 37 jC in an atmosphere of 5% CO2 and 95% air.
After incubation, cells were washed with PBS and lysed.
Caspase-3 activity was examined with 96-well plates in
duplicate for 90 min and absorbance was measured at 405
nm using a computer-interfaced 96-well microtiter plate
reader. As a positive control, H508 and SNU-C4 cells were
incubated with DCA (250 AM) for 1.5 h and 30 min,
respectively.
2.5. Radioligand binding
Binding of radioligand to muscarinic receptors on test
cell lines was examined using N-[3H-methyl]scopolamine
(3H-NMS, 82 Ci/mmol) (New England Nuclear, Boston,
MA). The 3H-NMS binding assay was performed as
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described previously [20]. Cells (28 106 cells/ml) were
incubated for 45 min at 22 jC with 0.6 nM 3H-NMS alone
or with unlabeled ligands in an incubation solution contain-
ing 50 mM Tris (pH 7.4), 5 mM MgCl2, 130 mM NaCl, 7.7
mM KCl, 1 mM EGTA, 4 Ag/ml leupeptin, 0.1% bacitracin
and 0.1% BSA. Nonsaturable binding was determined in the
presence of 10 AM unlabeled NMS and was < 20% of total
binding in all experiments. The reaction was terminated by
centrifuging 500 Al of cell suspension (10,000 g) for 7
min at room temperature. Supernatant (100 Al) was sampled
for determination of free ligand concentration, and the
remaining liquid was carefully decanted. The cell pellet
was washed, drained, and dissolved in 100 Al Soluene 350.
Ecoscint Awas added, and the radioactivity in the tubes was
measured in a liquid scintillation counter (1214 Rackbeta,
LKB/Wallac, Gaithersburg, MD). Values shown represent
binding with radioligand alone (total binding) minus non-
saturable binding. The concentration of agent that caused
50% inhibition of binding (IC50) was determined by using a
nonlinear, least-squares curve fitting program [31].
2.6. Inositol phosphates
Inositol phosphates were measured by previously
described methods [32]. Cells were seeded onto 6-well
plates at a density of 106 cells/well. After 18 h, growth
medium was removed from subconfluent cell monolayers,
and the cells were incubated with RPMI 1640 containing
myo-[2-3H(N)]-inositol (1 ACi/ml, New England Nuclear),
2% FBS at 37 jC for 24 h. Before the addition of agents to
be tested, cells were treated with 20 mM LiCl in PBS for 30
min. Phosphoinositide hydrolysis was initiated with the
addition of PI buffer (135 mM NaCl; 20 mM HEPES; 2
mM CaCl2; 1.2 mM MgSO4; 1.0 mM EGTA; 20 mM LiCl;
11.1 mM glucose and 0.05% BSA) containing various
concentrations of test agents. The incubation was allowed
to proceed at 37 jC for 30 min. The incubation was stopped
by adding 2 ml MeOH/HCl to each well. Total IPs (inositol
1-phosphate, inositol 1,4-bisphosphate and inositol 1,4,5-
trisphosphate) were purified by chromatography with AG1-
X8 resin (BioRad) and eluted with 1 mM ammonium
formate and 100 mM formic acid [33,34]. Hydrofluor was
added and radioactivity determined in a liquid scintillation
counter.
2.7. Statistical analysis
All data are reported as meanF SE of at least three
independent experiments. Statistical analysis was performed
using unpaired Student’s t-tests to determine significance
between two means. Statistical significance was set at P
values less than 0.05.
3. Results
3.1. Effects of bile acids on colon cancer cell proliferation
To determine whether, as observed with other cholinergic
agonists [27], LCT would stimulate proliferation of H508
cells, the cell lines were incubated with increasing concen-
trations of the bile acid for 6 days. Over the course of a 6-
day incubation, LCT caused a dose-dependent increase in
H508 cell proliferation (Fig. 1). Fig. 1a shows the time-
Fig. 1. Actions of LCT on proliferation of H508 colon cancer cells. Cells were seeded on 96-well plates and incubated for 6 days with the indicated
concentrations of LCT. Cellular proliferation was determined daily and expressed as optical density at 560 nm. Absorbance was determined after staining with
SRB, as described in Materials and methods. (a) Time-course for the effects of increasing concentrations of LCT on proliferation of H508 cells. (b) Dose–
response curve for the effect of LCT on H508 and SNU-C4 cells at 6 days. In each experiment, values were determined in triplicate and results given are means
from at least three separate experiments. (*) Indicates values that are significantly greater ( P < 0.05) than those for control cells incubated without LCT. Vertical
bars, SE.
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course for the effect on proliferation with increasing con-
centrations of the bile acid. With 100 and 300 AM LCT, a
significant increase in cell proliferation was first detected at
3 and 2 days, respectively. With the highest concentration
tested, 300 AM, the proliferative effects of LCT appeared to
plateau after the 5th day of incubation, achieving an approx-
imately 3-fold increase in proliferation. In the presence of 1
AM atropine (a concentration that did not significantly alter
basal proliferation), after the 5th day of incubation, LCT
(300 AM)-induced cell growth was inhibited to basal levels
(data not shown). Fig. 1b shows the dose–response curve
for LCT after 6 days of incubation. In the H508 cell line,
significant stimulation was observed with LCT concentra-
tions greater than 30 AM. In contrast, the SNU-C4 cells
showed no significant change in cellular proliferation.
3.2. Lack of cell toxicity with tested concentrations of bile
acids
To exclude cell damage as a reason for the differences in
cell proliferation, we evaluated potential toxic effects of bile
acid derivatives and DMSO, used as the solvent. We
examined the actions of the bile acids and cholinergic agents
on the exclusion of trypan blue from H508 and SNU-C4
cells. At concentrations used in the following experiments,
none of these agents altered this measure of cell damage.
Using conditions similar to those for cell proliferation and
IP formation, no trypan blue staining was observed in 200
counted cells. Hence, there was no evidence of cell damage
with these agents.
3.3. Effect of bile acids on apoptosis in H508 and SNU-C4
cells
To exclude apoptosis as a potential reason for the differ-
ences in cell proliferation, we evaluated the effects of bile
acid derivatives and the other agents tested on caspase-3
activity in H508 and SNU-C4 cells. Caspase-3 plays a
critical role in apoptosis [29] and caspase-3 activity has
been used as an index of apoptosis by several investigators
[30]. As shown in Fig. 2, after 3 and 6 days of incubation, in
both colon cancer cell lines, DCA, used as a positive control
[35], caused a 15- to 43-fold increase in apoptosis. This
increase was abolished by addition of a caspase-3 inhibitor.
In contrast, DMSO, carbachol and LCT had no effect on
caspase-3 activity in H508 or SNU-C4 cells. S-LCT caused
a small but significant increase in caspase-3 activation in
H508, but not SNU-C4 cells. These results indicate that
apoptosis is not the cause of the changes in cell proliferation
observed with the LA derivatives.
3.4. Effects of bile acids on binding of 3H-NMS to H508
cells
To determine the ability of LA conjugates to inhibit
binding of a known muscarinic receptor ligand to M3
receptors, we used a radioligand binding assay. Binding of
3H-NMS to H508 cells was examined alone, and in the
presence of increasing concentrations of cholinergic ago-
nists and conjugated derivatives of LA. Results of radio-
ligand binding are not shown for SNU-C4 cells because, as
published previously [26], 3H-NMS does not bind to SNU-
C4 cells. As shown in Fig. 3, acetylcholine (ACh), carba-
mylcholine (carbachol), LCT and LCG significantly
inhibited binding of the cholinergic radioligand. In contrast,
in the presence of S-LCT, the major human metabolite of
LCT [36], binding of the radioligand was the same as the
control. Inhibition of 3H-NMS binding was detectable with
50 AM LCT or 120 AM LCG. Inhibition of binding observed
with the maximal concentrations of LCT and LCG used, 250
and 600 AM, respectively, was approximately 25–30% of
that observed with maximal concentrations of ACh or
carbachol. Using a nonlinear, least-squares curve fitting
program, LIGAND [31], the concentrations of ACh, carba-
chol, LCT and LCG that caused half-maximal inhibition of
3H-NMS binding were 0.2, 0.3, 1.0 and 4.4 mM, respec-
tively. These results indicate that, in terms of inhibition of
3H-NMS binding, the bile acids are approximately 5 to 20
times less potent than ACh.
Fig. 2. Actions of LCT, S-LCT, carbachol and solvents on caspase-3
activity in H508 and SNU-C4 cells. (a) Caspase-3 activity in H508 cells
following incubation with indicated concentrations of test agents for 3 and 6
days. (b) Caspase-3 activity in SNU-C4 cells following incubation with
indicated concentrations of test agents for 3 and 6 days. In each experiment,
results given are means from at least three separate experiments. Vertical
bars, SE. (*, **) Indicates values that are significantly greater ( P< 0.05 and
0.001, respectively) than those for control cells.
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As shown in Fig. 4, although compared at different times,
the pattern of interaction for 100 AM carbachol, LCT, and S-
LCT was the same when comparing inhibition of 3H-NMS
binding to stimulation of cellular proliferation. That is, 100
AM carbachol and LCT caused similar inhibition of 3H-
NMS binding and stimulation of cellular proliferation,
whereas the same concentration of S-LCT caused a signifi-
cantly lesser effect on either parameter. This observation
supports the hypothesis that LCT-induced stimulation of
H508 cell proliferation is mediated by interaction with M3
muscarinic receptors. Neither LCT nor S-LCT (0.1–1000
AM) altered proliferation in the SNU-C4 cell line (data not
shown).
3.5. Effects of bile acids on cellular formation of IPs
To confirm that interaction of bile acids with muscarinic
receptors on H508 cells activates post-receptor signaling
pathways, we examined the actions of these agents on
cellular formation of IPs. Ligand interaction with M3
receptors stimulates activation of a guanine nucleotide bind-
ing (G) protein, Gq/11, with consequent activation of phos-
pholipase C and an increase in cellular IPs and calcium [37].
As shown in Fig. 5a, in H508 cells, maximal concentrations
of ACh and carbachol caused a robust, approximately 5-
fold, increase in IP formation. LCT and LCG also caused a
significant increase in cellular IP formation, but maximal
stimulation was approximately 5% of that observed with
ACh or carbachol (Fig. 5b). These results indicate that LA
conjugates interact with M3 muscarinic receptors on H508
cells to stimulate the same post-receptor signaling cascade
as ACh and carbachol. However, as expected, neither
cholinergic agonists nor bile acids altered IP formation in
SNU-C4 cells (Fig. 5a and b).
3.6. Effects of increasing concentrations of bile acids on
carbachol- and ACh-induced increases in IPs
To test further the hypothesis that conjugates of LA
interact with M3 muscarinic receptors on H508 cells, we
examined the actions of increasing concentrations of LCT
Fig. 4. Comparison of the actions of LCT on inhibition of 3H-NMS binding
to H508 cells and cell proliferation. (a) Actions of 100 AM carbachol, LCT
and S-LCT on 3H-NMS binding to H508 cells after 45 min incubation. (b)
Actions of 100 AM carbachol, LCT and S-LCT on H508 cell proliferation
after 6 days incubation. In each experiment, results given are means from at
least three separate experiments. (*, **) Indicates that response with S-LCT
is significantly less ( P < 0.05 and 0.001, respectively) than that observed
with carbachol or LCT. Vertical bars, SE.
Fig. 3. Actions of LCT on specific binding of 3H-NMS to H508 colon
cancer cells. H508 cells (28 106 cells/ml) were incubated for 45 min at 22
jC with 0.6 nM 3H-NMS and the indicated concentrations of ACh (open
triangles), carbachol (open squares), LCT (closed circles), LCG (closed
triangles) or 3-sul-LCT (S-LCT, open circles). Binding is expressed as the
percentage of 3H-NMS that was saturably bound in the absence of other
agents. 3H-NMS binding with the solvent for LCT, 0.6% DMSO, alone was
108.4F 5.4% control (not significantly different from control). In each
experiment, results given are means from at least three separate experi-
ments. (*, **) Indicates values that are significantly less ( P< 0.05 and
0.001, respectively) than 3H-NMS binding in the absence of added agents.
Vertical bars, SE.
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and LCG on ACh- and carbachol-induced increases in
cellular IPs (Fig. 6). We hypothesized that if these agents
were interacting with the same receptors, the less efficacious
agents (LCT and LCG) would inhibit the actions of sub-
maximal concentrations of the more efficacious agents
(ACh and carbachol). As shown in Fig. 6a, increasing
concentrations of LCT caused a progressive decrease in
ACh- and carbachol-induced IP production. A similar effect
was observed with LCG (Fig. 6b). In contrast, S-LCT did
not alter carbachol-induced IP production (data not shown).
These results support the hypothesis that the glycine and
taurine conjugates of LA interact with the same receptors on
H508 cells as ACh and carbachol.
4. Discussion
In animal models, increased concentrations of secondary
bile acids are associated with increased proliferation of
colorectal epithelium and the promotion of colon tumor
growth [14]. Beneficial properties of agents like calcium
and estrogens, that have been evaluated for chemopreven-
Fig. 5. Actions of ACh, carbachol, LCT, and LCG on H508 cellular IP formation in H508 and SNU-C4 cells. Cells (106 cells/well) were preincubated with
myo-[2-3H(N)]-inositol for 24 h at 37 jC, and the medium was replaced with a PBS solution containing 20 mM LiCl for 30 min. Cells were then incubated in
PI buffer, alone or with test agents for 30 min at 37 jC. Data are expressed as dpm in the IP fraction after separation by ion-exchange chromatography. (a)
Effect of increasing concentrations of ACh and carbachol on H508 and SNU-C4 cellular formation of IPs. (b) Effect of increasing concentrations of LCT and
LCG on H508 and SNU-C4 cellular formation of IPs. Results given are means from 3 to 11 separate experiments. (*, **) Indicates values that are significantly
greater ( P < 0.05 and 0.001, respectively) than control. Vertical bars, SE.
Fig. 6. Effects of LCT and LCG on the increase in IPs observed with submaximal concentrations of carbachol (closed circles) and ACh (open circles). (a)
Effects of increasing concentrations of LCT on ACh- and carbachol-induced IP formation. (b) Effects of increasing concentrations of LCG on ACh- and
carbachol-induced IP formation. Results given are means from at least three separate experiments. (*, **) Indicates values that are significantly less ( P < 0.05
and 0.001, respectively) than control. Vertical bars, SE.
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tion of colon cancer in humans, result from the binding or
reduced production of secondary bile acids [38]. Never-
theless, the mechanism whereby bile acids alter colonic
epithelial-cell turnover has not been elucidated.
In the present study, we provide evidence that conjugates
of LA stimulate colon cancer cell proliferation by muscar-
inic mechanisms. This includes the observations that LCT
and LCG dose-dependently compete with a muscarinic
radioligand for binding to M3 subtype receptors on cultured
human colon cancer cells [27], and stimulate an increase in
cellular formation of IPs. As predicted from the interaction
at the same receptor, increasing concentrations of LCT or
LCG inhibit IP formation by more efficacious cholinergic
agonists (ACh or carbachol). More importantly, LCT at
concentrations that inhibit 3H-NMS binding and stimulate
IP formation, increases proliferation of H508 cells and this
increase can be inhibited by the muscarinic receptor inverse
agonist atropine. Similar concentrations of LCT did not alter
proliferation of colon cancer cells (SNU-C4) that do not
express M3 receptors [27]. Moreover, LCT did not alter
apoptosis in either cell line.
To draw conclusions regarding the physiological or
pathophysiological implications of our observations, it is
necessary to demonstrate in vivo in the organ of interest that
LA derivatives achieve concentrations necessary for inter-
action with muscarinic receptors. In fact, concentrations of
LA derivatives in proximal animal and human colon have
been reported in the high micromolar to millimolar range
[39–41], particularly if ileal damage prevents enterohepatic
circulation. Hence, concentrations of LA conjugates that
interact with muscarinic receptors on H508 colon cancer
cells may be achieved in the normal colon. Moreover,
although the effects of LA derivatives on muscarinic radio-
ligand binding and stimulation of IP formation in H508 cells
are less than those observed with ACh, several factors argue
for a potential pathological role for the bile acids in vivo.
This includes: (a) the likelihood that fecal bile acids that are
normally found in stool will be in contact with colonic
epithelial cells for many years (the average age for devel-
oping colon cancer is greater than 50 years [1]); (b) LA
derivatives do not contain an ester linkage and, conse-
quently, will not be subject to hydrolysis by tissue chol-
inesterases that rapidly inactivate ACh; and (c) lipophilic
properties of monohydroxy LA derivatives allow these
agents ready access to muscarinic receptors in the lipid
bilayer of the colon cancer cell membrane.
Sulfation of LCT, a physiological detoxification mecha-
nism [36], abolishes the molecule’s ability to interact with
muscarinic receptors. LCT is hepatotoxic in species that lack
the enzyme necessary for sulfation [42]. The present study
suggests the possibility that alterations in the ability to
sulfate LA conjugates may alter initiation or progression
of colon cancer. It is of interest to note that a colon cancer
cell line has been reported to sulfate LA [43]. Hence, it may
be of interest to study possible genotypic or phenotypic
variation in expression of hepatic and colonic bile acid
sulfatases in subjects with and without advanced colon
cancer. Moreover, situations associated with decreased LA
conjugate sulfation, like advanced liver disease, may result
in augmented cholinergic actions of LA derivatives.
Although it is possible that chronic muscarinic receptor
stimulation may lead to colonic epithelial cell proliferation
and neoplastic transformation [3,44,45] the present studies
do not address this. We did not examine the effect of LA
derivatives on normal colonic epithelium. Nonetheless,
because we show that LCT stimulates proliferation of
already neoplastic cells, our data are compatible with the
hypothesis that LA derivatives enhance the growth of
existent cancer cells. Hence, once neoplastic transformation
occurs as a consequence of genetic mutation or other causes,
fecal bile acids may augment cancer cell proliferation and
consequently tumor growth. Whether the use of selective
anti-cholinergic agents or other approaches to blocking
potential interactions of bile acids with neoplastic colonic
epithelium is a useful adjunct to colon cancer prevention or
treatment remains to be determined.
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